NASDAQ: XGN · Industrial Applications and Services · 8 alerts · CIK 1274737
Share price
$3.77Close, Nov 16
Market cap
$96.2M
Shares outstanding
25.51MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Exagen Inc. filings on SEC EDGAR ↗
Exagen Insider Jorey Chernett Sells $746K of Stock
Jorey Chernett sold 167,504 shares of Exagen Inc. at $4.08 to $4.65 a share (average $4.45) in 2 transactions, worth $746K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 2,529,436 (-2.2%).
Jorey Chernett bought 71,315 shares of Exagen Inc. at $5.23 a share, worth $373K in total on Nov 11, 2026. Shares held after the trade: 2,696,940 (+2.7%).
Exagen Insider Jorey Chernett Buys $91.2K of Stock
Jorey Chernett bought 15,585 shares of Exagen Inc. at $5.26 to $6.35 a share (average $5.85) in 2 transactions, worth $91.2K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,625,625 (+0.3%).
Exagen Insider Jorey Chernett Sells $69.2K of Stock
Jorey Chernett sold 11,265 shares of Exagen Inc. at $6.14 a share, worth $69.2K in total on Nov 6, 2026. Shares held after the trade: 2,610,040 (-0.4%).
Exagen Inc. reported revenue of $18.4 million for Q3 2026, a 6.8% increase year-over-year, while narrowing its net loss to $6.3 million compared to $7.1 million in Q3 2025. The company strengthened its capital position through $6.4 million in net proceeds from an at-the-market (ATM) equity offering during the quarter.
Exagen Inc. reported third quarter 2026 revenue of $18.4 million, a 7% increase year-over-year, driven by growth in test volume and average selling price. The company reduced its net loss to $6.3 million for the quarter and reiterated its full-year 2026 revenue guidance of $72 million to $75 million.
Term
Q3 2026
“Our third quarter extends what is fast becoming a record year for Exagen, and our ability to execute against our vision is increasingly evident in the results. The team grew the business again, with test volume and ASP both ahead of the same period last year.”
John Aballi, President and Chief Executive Officer of Exagen
Jorey Chernett bought 14,000 shares of Exagen Inc. at $7.46 a share, worth $104K in total on Oct 19, 2026. Shares held after the trade: 2,618,540 (+0.5%).
Exagen President and CEO John Aballi Sells $270K of Stock
John Aballi, President and CEO, sold 34,294 shares of Exagen Inc. at $7.87 a share, worth $270K in total on Oct 16, 2026. Shares held after the trade: 805,540 (-4.1%).